Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review.

Fiche publication

Date publication

novembre 2021

Journal

Current medical research and opinion

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MONASSIER Laurent , Dr BECKER Guillaume

Tous les auteurs :
Becker G, Rougerie F, Sabo AN, Dalmas MC, Ayme-Dietrich E, Monassier L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34412518

Résumé

Bradykinin-mediated angioedema is a rare but potentially fatal adverse event. Angioedema induced by angiotensin-converting enzyme (ACE) inhibitors is generally attributed to an inhibition of bradykinin degradation following ACE inhibition. Clinical studies on ACE inhibitors mainly focus on their efficacy. Few examine their potential to generate undesirable adverse effects, particularly with regard to angioedema.